As per DelveInsight’s epidemiological analysis, Adrenoleukodystrophy prevalence in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) was estimated to be 55,242 in 2017.
DelveInsight reckons an increase in the global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 million in the 7MM in 2017.
Some of the Key pharma players involved in the development of therapies to address the unmet needs prevailing in the Adrenoleukodystrophy market include Bluebird Bio, Minoryx Therapeutics, Medday Pharmaceuticals, Magenta Therapeutics, and others.
For more details visit: https://www.delveinsight.com/blog/adrenoleukodystrophy-market-size/